Drug safety reporting · source selection
The best official source depends on the claim. A current FDA label supports approved labeling; a recall record supports a recall; a shortage entry supports national shortage status. One record should not be asked to prove a different event.
Match the record to the sentence
FDA’s Drug Safety and Availability page routes readers to safety communications, alerts and statements, labeling changes, recalls, compounding information, shortage records, REMS and MedWatch. These sources overlap in topic but not in evidentiary function.
Before drafting, write the proposed factual sentence and name the record type that could directly verify it. If the sentence says a product was recalled, a general safety communication is not enough. If it says labeling changed, a media report is not a substitute for the dated FDA-approved label.
Search-engine snippets and agency index pages can help locate a record, but they may omit qualifiers or later updates. The evidence file should preserve the exact linked document and the context surrounding the quoted claim.
An editorial source ladder
- Exact product record: application number, current label and approval action.
- Exact agency action: recall, safety communication, warning letter, alert or REMS record.
- Surveillance source: MedWatch or adverse-event dashboards, with their causal and denominator limits.
- Agency overview: useful for definitions and navigation, not product-specific conclusions.
- Secondary reporting: context only after the primary record is found and checked.
A safety signal, label change and recall can occur on different dates and carry different scopes. Build a dated chain of evidence instead of treating them as synonyms.
Fields every source box should show
- Agency and exact document or database title
- Product, application, lot or population identifiers where relevant
- Publication, update and retrieval dates
- Jurisdiction and audience
- Known limitations and any later linked action
What remains outside the newsroom
Source selection can make a report more accurate, but it cannot answer whether an individual should take, stop or replace a medicine. Personal decisions belong with a licensed clinician or pharmacist who can assess the patient and the exact product.
For a patient-facing example of that separate clinical route, see the patient-facing finasteride evaluation and prescription pathway, which keeps individual evaluation, prescribing and pharmacy fulfillment distinct from the source hierarchy used for reporting.